Nicusor Iftimia | Precision Medicine | Innovative Research Award | 2701

Published on 17/07/202617/07/2026 by Top Pharmaceutical

Innovative Research Award

Nicusor Iftimia
PSI, United States

Research Profile
Affiliation	PSI
Country	United States
Scopus ID	6603766089
Documents	177
Citations	4,524
h-index	36
Subject Area	Precision Medicine
Event	International Top Pharmaceutical Awards
ORCID	0000-0002-7713-6972

The Innovative Research Award recognizes researchers whose sustained scientific contributions have significantly advanced their respective disciplines through original research, technological innovation, and scholarly impact. Nicusor Iftimia has established a distinguished research profile in precision medicine and biomedical imaging, with extensive publications, a strong citation record, and interdisciplinary contributions that have influenced translational healthcare research.[1] His scholarly work spans optical imaging technologies, diagnostic instrumentation, and clinical applications that support improved patient outcomes.[2]

Contents

Abstract
Keywords
Introduction
Research Profile
Research Contributions
Publications
Research Impact
Award Suitability
Conclusion
External Links
References

Abstract

Nicusor Iftimia has developed an internationally recognized research portfolio focused on precision medicine, biomedical optics, and advanced diagnostic technologies. His scientific investigations have supported improvements in optical coherence tomography, image-guided diagnostics, and translational biomedical engineering. The combination of a high publication output, extensive citations, and measurable scholarly influence demonstrates the sustained academic excellence expected for recognition through the Innovative Research Award.[1]

Keywords

Precision Medicine, Optical Coherence Tomography, Biomedical Imaging, Diagnostic Instrumentation, Biomedical Engineering, Clinical Imaging, Medical Devices, Translational Medicine, Optical Diagnostics, Innovative Research.

Introduction

Precision medicine continues to transform healthcare by integrating advanced imaging technologies with patient-specific diagnostic strategies. Researchers working at the intersection of engineering, optics, and medicine contribute substantially to this evolving field through innovations that improve disease detection and clinical decision-making. Nicusor Iftimia has consistently contributed to these developments through multidisciplinary research involving optical technologies and biomedical instrumentation.[2]

Research Profile

Nicusor Iftimia has established a distinguished research profile in precision medicine through extensive contributions to biomedical optics, optical coherence tomography, and advanced medical imaging technologies. His academic portfolio comprises 177 Scopus-indexed publications, more than 4,524 citations, and an h-index of 36, demonstrating sustained scholarly productivity and international research influence. His work emphasizes the development of innovative diagnostic methods and translational biomedical engineering solutions that bridge laboratory research with clinical practice. The breadth of his publications, collaborative research activities, and measurable scientific impact highlight his continued contributions to advancing precision medicine and healthcare technologies.[1][2]

Research Contributions

The research contributions of Nicusor Iftimia emphasize the integration of optical technologies with clinical practice. His publications have supported advances in non-invasive imaging, medical diagnostics, and translational biomedical engineering, enabling more accurate disease assessment and supporting innovation within precision healthcare systems.[3]

Publications

Nicusor Iftimia has authored 177 Scopus-indexed publications covering precision medicine, biomedical optics, optical coherence tomography, medical imaging, and diagnostic instrumentation. His scholarly work has been published in internationally recognized peer-reviewed journals and conference proceedings, demonstrating consistent research productivity and interdisciplinary collaboration. These publications have significantly contributed to the advancement of non-invasive imaging technologies, clinical diagnostics, and translational biomedical engineering. The sustained quality and impact of his research output are reflected by a strong citation record and continued recognition within the global scientific community.[1][2]

Research Impact

The citation metrics and publication record indicate sustained international recognition within biomedical engineering and medical imaging. The research has contributed to technological innovation, interdisciplinary collaboration, and scientific knowledge transfer across academic and healthcare communities.[1]

Award Suitability

Based on measurable scholarly indicators, interdisciplinary research contributions, and international scientific visibility, Nicusor Iftimia demonstrates characteristics consistent with the objectives of the International Top Pharmaceutical Awards. His sustained research productivity, technological innovation, and influence within precision medicine provide a strong academic foundation for consideration for the Innovative Research Award.[4]

Conclusion

Nicusor Iftimia’s academic profile reflects long-term excellence in biomedical optics, precision medicine, and diagnostic innovation. His publication history, citation impact, and interdisciplinary research achievements illustrate continued contributions to scientific advancement and demonstrate the qualities recognized through international research excellence awards.[1]

External Links

References

Elsevier. (n.d.). Scopus author details: Nicusor Iftimia, Author ID 6603766089. Scopus. https://www.scopus.com/authid/detail.uri?authorId=6603766089
Iftimia, N., Yadav, P., Primrose, M., Maguluri, G., Jones, J., Grimble, J., & Sheth, R. A. (2026). AI-Assisted OCT Imaging for Core Needle Biopsy Guidance: The 1st in Humans Study. https://doi.org/10.3390/diagnostics16050811
Sampani, K., Mujat, M., Patel, A. H., Kang, C., Iftimia, N., Chatziralli, I., & Sun, J. K. (2024). Characterizing Vascular Wall and Lumen Caliber in Eyes with Diabetic Retinopathy Based on Adaptive Optics Scanning Laser Ophthalmoscopy. https://doi.org/10.3390/diagnostics14182020
Steinberg, R., Meehan, J., Tavrow, D., Maguluri, G., Grimble, J., Primrose, M., & Iftimia, N. (2024). Assessing Lung Fibrosis with ML-Assisted Minimally Invasive OCT Imaging.https://doi.org/10.3390/diagnostics14121243
Maguluri, G., Grimble, J., Mujat, M., Park, J., Caron, A., & Iftimia, N. (2022). Fiber-based hand-held RCM-OCT probe for noninvasive assessment of skin lesions and therapy guidance. https://doi.org/10.1002/tbio.202200002

Mihaela Minea | Personalized Medicine | Best Researcher Award

Published on 23/05/202623/05/2026 by Top Pharmaceutical

Best Researcher Award

Mihaela Minea — Ovidius University of Constanța

Mihaela Minea
Affiliation	Ovidius University of Constanța
Country	Romania
Scopus ID	58509570100
Documents	65
Citations	67
h-index	4
Subject Area	Personalized Medicine
Event	International Top Pharmaceutical Awards

Mihaela Minea is associated with Ovidius University of Constanța, Romania, and has contributed to the interdisciplinary field of personalized medicine, rehabilitation sciences, and clinical evaluation methodologies. Her academic profile reflects scholarly engagement in rehabilitation assessment, gait analysis, and evidence-based healthcare approaches relevant to modern pharmaceutical and therapeutic research practices.[1] Her publication activity and citation profile demonstrate continuing participation in applied medical research with emphasis on patient-centered clinical outcomes and rehabilitation innovation.[2]

Contents

Abstract
Keywords
Introduction
Research Profile
Research Contributions
Publications
Research Impact
Award Suitability
Conclusion
External Links
References

Abstract

This academic recognition article presents an overview of the scholarly profile and research contributions of Mihaela Minea in the domain of personalized medicine and rehabilitation sciences. Her work includes research on computerized gait analysis, rehabilitation outcomes, and clinical assessment methodologies. The research profile demonstrates involvement in interdisciplinary healthcare research integrating rehabilitation sciences with evidence-based medical evaluation frameworks. The publication record and citation activity indicate continuing academic participation in applied medical and pharmaceutical research relevant to patient-centered healthcare advancement.[1][3]

Keywords

Personalized Medicine, Rehabilitation Sciences, Clinical Research, Gait Analysis, Evidence-Based Medicine, Pharmaceutical Research, Osteoarthritis Rehabilitation, Healthcare Innovation, Medical Assessment, Research Evaluation

Introduction

Personalized medicine has become an important area within modern healthcare systems due to its focus on individualized therapeutic strategies, rehabilitation optimization, and patient-centered clinical interventions. Researchers working in this field contribute to the development of assessment methodologies that improve rehabilitation outcomes and evidence-based healthcare decision-making. Mihaela Minea has participated in research activities related to rehabilitation analysis and clinical outcome assessment, particularly within gait evaluation and osteoarthritis rehabilitation studies.[2] Such investigations support broader advancements in clinical rehabilitation sciences and therapeutic monitoring systems relevant to pharmaceutical and healthcare applications.[4]

Research Profile

The research profile of Mihaela Minea includes scholarly contributions indexed within Scopus author databases and related scientific platforms. Her documented academic activities involve publications associated with rehabilitation medicine, gait analysis technologies, and clinical healthcare evaluation systems.[1] The available citation metrics indicate an active contribution to interdisciplinary medical research with recognized engagement in healthcare-oriented investigations. The combination of publication records, citation activity, and subject specialization demonstrates sustained involvement in patient-focused rehabilitation studies and evidence-driven clinical methodologies.[5]

Research Contributions

The documented research contributions of Mihaela Minea include involvement in studies examining rehabilitation outcomes and computerized gait analysis systems for patients affected by knee osteoarthritis. These studies contribute to the understanding of rehabilitation effectiveness and objective clinical evaluation approaches in musculoskeletal healthcare management.[2] Research activities in rehabilitation sciences are increasingly relevant for modern healthcare systems because they support therapeutic optimization, monitoring strategies, and individualized rehabilitation planning. The integration of digital analysis tools into rehabilitation research also reflects broader trends in precision medicine and data-informed healthcare delivery.[6]

Publications

Selected scientific publications associated with Mihaela Minea demonstrate research interest in rehabilitation science, clinical assessment methodologies, and gait analysis applications in osteoarthritis rehabilitation.[2] These publications contribute to the broader scientific understanding of rehabilitation monitoring and healthcare evaluation systems relevant to personalized therapeutic approaches.[3]

Research Impact

Research impact within rehabilitation sciences is often evaluated through publication indexing, citation activity, and interdisciplinary relevance. The available citation record associated with Mihaela Minea indicates academic recognition within clinical and rehabilitation research communities.[1] Her scholarly work contributes to evidence-based rehabilitation practices and supports continuing discussions regarding digital clinical assessment technologies and patient-centered rehabilitation models. Such contributions are relevant to healthcare professionals, rehabilitation specialists, and medical researchers interested in outcome-oriented therapeutic evaluation systems.[4]

Award Suitability

Mihaela Minea demonstrates suitability for recognition through the Best Researcher Award based on her documented academic contributions, indexed research profile, and participation in rehabilitation and personalized medicine studies. Her scholarly activities align with the objectives of the International Top Pharmaceutical Awards, which recognize meaningful scientific engagement and interdisciplinary healthcare research contributions.[5] The combination of research activity, publication records, and citation visibility supports recognition within professional academic and clinical research environments. Her contributions further reflect continuing efforts toward evidence-based rehabilitation assessment and healthcare innovation.[6]

Conclusion

Mihaela Minea has contributed to the advancement of rehabilitation sciences and personalized medicine through scholarly participation in gait analysis and clinical rehabilitation research. Her academic profile reflects interdisciplinary engagement in evidence-based healthcare methodologies and rehabilitation assessment systems. The indexed research record, citation activity, and continuing relevance of her scientific work support recognition within professional medical and pharmaceutical research communities. These contributions remain relevant to contemporary discussions surrounding patient-centered healthcare, rehabilitation optimization, and digital clinical evaluation technologies.[1][3]

External Links

References

Elsevier. (n.d.). Scopus author details: Mihaela Minea, Author ID 58509570100. Scopus.https://www.scopus.com/authid/detail.uri?authorId=58509570100
Minea, M., et al. (2023). Using Computerised Gait Analysis to Assess Changes After Rehabilitation in Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Gait Speed Improvement. Healthcare.DOI: https://doi.org/10.3390/healthcare11050639

Miao Zhou | Precision Medicine | Best Researcher Award

Published on 24/07/202524/07/2025 by Top Pharmaceutical

Miao Zhou | Precision Medicine | Best Researcher Award

Prof. Miao Zhou at Guangdong Provincial People’s Hospital, China.

Dr. Miao Zhou is a distinguished oral and maxillofacial specialist, currently serving as Chief Physician and Associate Director at the Stomatology Department of Guangdong Provincial People’s Hospital. He is also a supervisor of postgraduate and postdoctoral researchers. An innovator in oral regenerative medicine, he founded the 3D Bioprinting and Regenerative Medicine Branch of the Guangdong Society of Biomedical Engineering. His pioneering research bridges clinical practice and cutting-edge biotechnology, advancing solutions for complex craniofacial conditions. With deep expertise in biomaterials, stem cells, and exosomes, Dr. Zhou continues to drive impactful research and medical education in the fields of maxillofacial rehabilitation and tissue engineering.

Publication Profile

Scopus

Education

Dr. Miao Zhou earned his Ph.D. in 2009 from Peking University, one of China’s top-tier institutions, where he focused on maxillofacial rehabilitation using functional biomaterials and tissue engineering. His doctoral thesis explored clinical solutions for oral and maxillofacial defects through bio-integrative materials and scaffold systems. This strong academic foundation laid the groundwork for his later interdisciplinary innovations in regenerative medicine. In addition to his formal education, Dr. Zhou has participated in numerous continuing education programs and scientific collaborations, refining his expertise in 3D printing, stem cell therapy, and implantology, and training the next generation of specialists in advanced dental medicine.

Experience

With over 15 years of clinical and research experience, Dr. Miao Zhou is a Chief Physician and Associate Director at Guangdong Provincial People’s Hospital’s Stomatology Department. He supervises both postgraduates and postdocs, guiding translational research in tissue regeneration. He has served as Principal Investigator on numerous national and provincial-level projects, especially in the application of 3D-printed biomimetic scaffolds and exosomes. As a research leader, Dr. Zhou has pioneered innovations in craniomaxillofacial bone regeneration and soft tissue reconstruction. His clinical expertise, combined with academic leadership, positions him as a key influencer in oral regenerative therapy and personalized medical biomaterial development.

Awards

Dr. Zhou has received numerous accolades, including the First Prize for Excellent Paper at the 6th China International & 9th China Academic Conference of Oral and Maxillofacial Surgery. His recognition reflects significant contributions to clinical and translational research. He has been honored by national bodies such as the National Natural Science Foundation of China and the Guangzhou Healthcare Innovation Program for his leadership in 3D bioprinting and regenerative medicine. As the founder of the 3D Bioprinting and Regenerative Medicine Branch under the Guangdong Society of Biomedical Engineering, his efforts have helped shape emerging medical frontiers and drive collaborative innovation.

Research Focus

Dr. Zhou’s research centers on 3D-printed biomimetic scaffolds, stem cell therapy, and exosome-based interventions for oral and maxillofacial regeneration. His work explores how engineered tissues and cell-based therapies can reconstruct large jaw defects, restore bone function, and integrate with host tissues. His studies focus on osteoinduction, vascularization, and personalized medicine approaches using biocompatible materials. By leveraging cutting-edge printing technologies and biomolecular signaling pathways, Dr. Zhou aims to bridge gaps between laboratory research and clinical application—delivering impactful solutions for tissue repair and oral implantology. His interdisciplinary approach integrates biomaterials science, dentistry, and regenerative medicine to redefine patient care.

Publication Top Notes

An engineered M2 macrophage-derived exosomes-loaded electrospun biomimetic periosteum promotes cell recruitment, immunoregulation, and angiogenesis in bone regeneration

Osteogenically committed hUCMSCs-derived exosomes promote the recovery of critical-sized bone defects with enhanced osteogenic properties

3WJ RNA Nanoparticles-Aptamer Functionalized Exosomes From M2 MacrophagesTarget BMSCs to Promote the Healing of Bone Fractures

Mario Romeo | Precision Medicine | Best Researcher Award

Published on 02/07/202502/07/2025 by Top Pharmaceutical

Mario Romeo | Precision Medicine | Best Researcher Award

Dr. Mario Romeo, Dipartimento di Medicina di Precisione, Università degli Studi della Campania, LuigiVanvitelli, Italy

Dr. Mario Romeo is an accomplished medical doctor and researcher specializing in Digestive System Diseases. Graduating with top honors in Medicine and Surgery from the University of Campania “Luigi Vanvitelli” 🎓, he also earned a specialization in Gastroenterology and is pursuing a Ph.D. in Clinical and Experimental Medical Sciences. His research spans gut microbiota 🧫, liver disease 🏥, and metabolic dysfunction. A recipient of over 20 international awards 🏆, Dr. Romeo is widely recognized for his groundbreaking work in hepatology and gastroenterology. He actively contributes to scientific societies and fosters innovation in digestive health care.

Publication Profile

Orcid

Education

Dr. Mario Romeo 🎓 began his academic journey with honors, earning his Diploma di Maturità Classica from Liceo Classico Gneo Nevio in June 2014 with a perfect score of 100/100 con lode 📜. He continued his excellence at the University of Campania “Luigi Vanvitelli,” completing his Laurea in Medicina e Chirurgia in July 2020 with 110/110 con lode 🩺, presenting a thesis on sarcopenia in compensated liver cirrhosis. He further specialized in Digestive System Diseases, earning his diploma in January 2025 with 50/50 con lode 🌟. His thesis explored RPR as a non-invasive tool in liver disease prediction.

Awards

Dr. Mario Romeo 🏅 has received numerous prestigious scholarships and awards in recognition of his excellence in hepatology and gastroenterology. Highlights include competitive fellowships like the AISF MasterClass 2022 🎓 and UEG Clinical Visiting Fellowship 2025 🌍. He has earned multiple travel grants ✈️ and best presentation prizes 🏆 at top events such as UEG Week, FISMAD, EASL, and ESCI for groundbreaking research on liver diseases, MAFLD, gut microbiota, and non-invasive biomarkers. His multidisciplinary “CoCoNut” protocol 🍏 also gained international acclaim. These accolades affirm his dynamic role in advancing liver research and patient care through innovation and collaboration.

Research Focus

Dr. Mario Romeo’s research focus lies predominantly in Hepatology and Gastroenterology, with a strong emphasis on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), liver cirrhosis, and gut-liver axis dynamics 🧬🍽️. His work explores non-invasive biomarkers, body composition, oxidative stress, and gut microbiota 🧫, highlighting their roles in disease progression and clinical outcomes. He also investigates multidisciplinary management strategies combining nutritional, psychological, and pharmacological interventions 🥗🧠💊. Dr. Romeo contributes significantly to understanding liver-related complications like sarcopenia, dysgeusia, and hepatocellular carcinoma 🎯. His innovative, patient-centered research enhances predictive diagnostics and therapeutic approaches in chronic liver diseases.

Publication Top Notes

Spleen Area Affects the Performance of the Platelet Count–Based Non-invasive Tools in Predicting First Hepatic Decompensation in Metabolic Dysfunction–Associated Steatotic Liver Disease Cirrhosis

Nutritional and Psychological Support as a Multidisciplinary Coordinated Approach in the Management of Chronic Liver Disease: A Scoping Review

Letter: Different Risk of Acute Variceal Bleeding According to the Liver Disease Aetiology in Decompensated Cirrhosis Patients Receiving Carvedilol‐Based Primary Prophylaxis—May Insulin Resistance Unloose This Gordian Knot?

Exploring the Classic and Novel Pathogenetic Insights of Plastic Exposure in the Genesis and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

The Role of the Gut–Biliary–Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications

Primary biliary cholangitis, Celiac Disease, and MASLD: the triumvirate of steatosis. How should we manage this triple overlap?

Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?

FLAME: Training and Validating a Newly Conceived Model Incorporating Alpha-Glutathione-S-Transferase Serum Levels for Predicting Advanced Hepatic Fibrosis and Acute Cardiovascular Events in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Dysgeusia in MASLD-related advanced chronic liver disease (ACLD): a silent driver towards the “Bermuda” triangle of malnutrition-sarcopenia-frailty severely affecting prognosis

Vanek’s Tumour as a Rare Cause of Dyspeptic Syndrome in a Patient with Primary Biliary Cholangitis: A Case Report

Systemic Oxidative Stress Correlates with Sarcopenia and Pruritus Severity in Primary Biliary Cholangitis (PBC): Two Independent Relationships Simultaneously Impacting the Quality of Life—Is the Low Absorption of Cholestasis-Promoted Vitamin D a Puzzle Piece?

Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study

IOANNIS VAMVAKARIS | Precision Medicine | Best Researcher Award

Published on 11/06/202511/06/2025 by Top Pharmaceutical

IOANNIS VAMVAKARIS | Precision Medicine | Best Researcher Award

Dr. IOANNIS VAMVAKARIS, IATROPOLIS, Greece

Dr. Ioannis Vamvakaris is a distinguished Greek pathologist specializing in thoracic pathology. 🫁 He earned his MSc in Thoracic Oncology in 2013 and PhD in 2018 from Athens School of Medicine. 🎓 Since 2019, he has led the Pathology Department at Sotiria General Hospital. 🏥 He’s authored over 200 publications 📚 and co-developed Greece’s first AI software for pathology. 🤖 A reviewer for top journals (Elsevier, MDPI), he actively collaborates on global research in cancer, organoids, proteomics, and microbiome. 🌍 Recognized with the 2024 Best Researcher Award 🏆 and Sigma Xi membership, Dr. Vamvakaris continues to shape medical science with dedication and innovation.

Publication Profile

Google Scholar

Education

Dr. Ioannis Vamvakaris is a highly accomplished pathologist who began his medical journey at Sotiria General Hospital in Athens 🏥. Since 2008, he has served as a consultant in the pathology department, demonstrating unwavering dedication to thoracic pathology 🫁. He earned his MSc in Thoracic Oncology in 2013 and completed his PhD in 2018 from the Athens School of Medicine 🎓. Dr. Vamvakaris also pursued specialized training in Patient-Crisis-Emergency Management at the Berlin School of Economics 🇩🇪. His academic growth and professional excellence highlight his strong commitment to advancing medical knowledge and enhancing patient care globally 🌍.

Awards

Dr. Ioannis Vamvakaris has earned prestigious honors in recognition of his exceptional contributions to pathology and oncology research 🔬. In 2024, he was presented with the Best Researcher Award at the International Research Awards on Oncology and Cancer Research 🧬. That same year, he was inducted as an Associate Member of Sigma Xi 🧠—a globally respected scientific research honor society that recognizes excellence through nomination only. Additionally, he received the Trusted Reviewer Certificate in 2023 📄, reflecting his outstanding commitment to scientific publishing and peer evaluation. These accolades underscore his leadership and integrity in medical science 🌟.o

Research Focus

Dr. Ioannis Vamvakaris is a leading expert in thoracic pathology, with a strong research focus on lung cancer, molecular oncology, and immunopathology 🔬. His studies span non-small cell lung cancer (NSCLC), checkpoint inhibitor-induced sarcoidosis, and PD-1/PD-L1 immune responses 🧬. His collaborative work explores liquid biopsy biomarkers, xenograft models, and AI-assisted diagnostics 🤖. Passionate about translational research, he contributes to genomics, proteomics, fibrosis, and epigenetics in thoracic malignancies. His multidisciplinary efforts bridge clinical pathology and personalized medicine, advancing early diagnosis and targeted therapies 💉. Dr. Vamvakaris’ research enriches global understanding of lung diseases and thoracic oncology 🌍.

Publication Top Notes

Sarcoidosis-like reactions induced by checkpoint inhibitors

Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts

Epithelial–mesenchymal transition in non small-cell lung cancer

Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer

Sputum and BAL Clara cell secretory protein and surfactant protein D levels in asthma

DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection

Concurrent granulomatous hepatitis, pneumonitis and sepsis as a complication of intravesical BCG immunotherapy

Salivary inflammatory markers in tension type headache and migraine: the SalHead cohort study

Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic …

An immunohistochemical evaluation of the proteins W nt1 and glycogen synthase kinase (GSK)‐3β in invasive breast carcinomas

Pulmonary blastoma: a comprehensive overview of a rare entity

Preoperative mutational analysis of circulating tumor cells (CTCs) and plasma-cfDNA provides complementary information for early prediction of relapse: A pilot study in early …

Jian Shi | Precision Medicine | Best Researcher Award

Published on 10/06/202510/06/2025 by Top Pharmaceutical

Jian Shi | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Jian Shi, Neurology of UCSF, United States

Assoc. Prof. Dr. Jian Shi is a distinguished neuroscientist at the University of California, San Francisco, with a Ph.D. in Neurobiology from Navy Medical University, China. 🧬 He completed postdoctoral training at the University of Texas Southwestern Medical Center, focusing on neuroscience. His research integrates brain injury, neurodegenerative diseases, and glioblastoma with cutting-edge AI and bioinformatics tools. 🧪🧠 Dr. Shi has authored highly cited publications and received numerous accolades, including the APS Outstanding Paper Award. 🌟 A dedicated mentor and educator, he actively contributes to diversity and public service in neurology and biomedical research.

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Jian Shi began his academic journey at the National University of Defense Technology in Hunan Province, China, earning both his B.S. and M.S. degrees in Biomechanics. ⚙️📘 He then pursued his Ph.D. in Neurobiology under the mentorship of Dr. Lu Changlin at the prestigious Navy Medical University in Shanghai. 🧬🏥 Driven by a passion for neuroscience, he completed his postdoctoral training at the University of Texas Southwestern Medical Center under the guidance of Dr. Steven G. Kernie, focusing on advanced neuroscience research. 🧠🔬 His academic foundation bridges biomechanics and cutting-edge neurobiological science.

Awards

Assoc. Prof. Dr. Jian Shi has received numerous accolades recognizing his excellence in research and education. 🇨🇳 He was honored with the prestigious National Award for Scientific Progress, Level 2 in China 🥇🔬 and received the Award for Outstanding Scientists from Navy Medical University, where he also earned the Best Teacher Award for his commitment to academic excellence 👨‍🏫🌟. His groundbreaking work earned him the “Top 50 Most Cited Article Award” from the Journal of Clinical Medicine 📖📈 and the APS Outstanding Paper Award from Acta Pharmacologica Sinica 🧪🏅. He is also recognized as a Trusted Reviewer by the International Journal of Molecular Sciences 🧠✅.

Research Focus

Assoc. Prof. Dr. Jian Shi’s research centers around neurobiology, with a strong emphasis on traumatic brain injury (TBI) 🧠💥, neurodegeneration 🧬, neurogenesis 🌱, and molecular neuroscience. His work explores small molecule therapies, microglial activation, intranasal drug delivery 💊, and microRNA biomarkers, particularly in the context of glioblastoma and stroke. He also investigates brain repair mechanisms, exosomal signaling 📦, and neurotrophin-mimetic compounds. In recent years, his interdisciplinary work has extended to climate impact models 🌍 and machine learning applications 🤖 in brain science, reflecting a comprehensive and innovative research portfolio in translational neuroscience and brain health.

Publication Top Notes

Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents

Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor

Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia

Considering exosomal miR-21 as a biomarker for cancer

The basic helix-loop-helix transcription factor olig2 is critical for reactive astrocyte proliferation after cortical injury

A small molecule p75^NTR ligand protects neurogenesis after traumatic brain injury

MicroRNAs as biomarkers for human glioblastoma: progress and potential

Regulatory networks between neurotrophins and miRNAs in brain diseases and cancers

Triggering receptor expressed on myeloid cells-2 expression in the brain is required for maximal phagocytic activity and improved neurological outcomes following experimental …

Beneficial effects of minocycline and botulinum toxin–induced constraint physical therapy following experimental traumatic brain injury

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Published on 22/04/202522/04/2025 by Top Pharmaceutical

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Dr. Nigatu Gebrehiwot, Zhengzhou University, China

Dr. Nigatu Gebrehiwot is a dedicated PhD candidate in Pharmacology at Zhengzhou University, China, specializing in drug safety evaluation. He holds a Master’s in Clinical and Administrative Pharmacy from Xi’an Jiaotong University and a Bachelor of Pharmacy from Mekelle University, where he was recognized as an outstanding student. A published researcher and global presenter, Dr. Gebrehiwot has earned accolades including recognition at ISPOR in Barcelona. He is actively involved in multiple international scientific societies and brings strong expertise in pharmacotherapy, academic writing, and collaborative healthcare research. His work explores methionine metabolism and innovative therapeutic strategies.

Publication Profile

Orcid

Education

Dr. Nigatu Gebrehiwot holds a Master’s degree in Clinical and Administrative Pharmacy from Xi’an Jiaotong University, where his research earned an award at the 21st European Congress ISPOR Health Outcome Research Conference in Barcelona, Spain. 🏅 He also earned a Bachelor’s degree in Pharmacy from Mekelle University, where he was recognized as the most outstanding student in his class. 🎓 His academic achievements reflect his dedication to advancing the field of pharmacy, blending clinical expertise with research excellence. Dr. Gebrehiwot’s work continues to impact the healthcare landscape positively.

Experience

Dr. Nigatu Gebrehiwot is currently a Ph.D. candidate in Pharmacology at the Center for Drug Safety Evaluation and Research, Zhengzhou University, Henan, China, since September 2022. 🎓 Prior to this, he served as the Principal Scientific Officer at the Federal Ministry of Health (FMOH) in Ethiopia from June 2020 to 2021. During his tenure, Dr. Gebrehiwot managed national disease programs and medicines, overseeing the funding and evaluation of treatment guidelines and drug therapy protocols in accordance with Ethiopian legislation and EFDA guidelines. 💊 He also led technical committees focused on antimicrobial therapy, cancer, and chronic disease management.

Awards

Dr. Nigatu Gebrehiwot received a prestigious award for his research abstract at the 21st European Congress ISPOR Health Outcome Research conference in Barcelona, Spain. 🏆 This recognition underscores the significant impact of his work in the field of pharmacology and health outcome research. 🌍 His contributions continue to advance knowledge and influence healthcare practices, making him a respected figure in his field. 💡 Dr. Gebrehiwot’s dedication to research excellence and his ability to address critical health issues have earned him well-deserved acknowledgment on an international stage.

Research Focus

Dr. Nigatu Tadesse’s research primarily focuses on molecular alterations in disease processes, with an emphasis on metabolic pathways and their potential as diagnostic and therapeutic targets. His work on gastric intestinal metaplasia and methionine metabolism sheds light on novel approaches to diagnosis and treatment. Additionally, Dr. Tadesse has contributed significantly to pharmacology, particularly the study of traditional medicines like Dioscorea zingiberensis, investigating its phytochemistry, clinical applications, and toxicity. His research also extends to industrial processes, such as wastewater treatment in diosgenin production. His interdisciplinary work connects biomedicine, pharmacology, and environmental science.

Publication Top Notes

Molecular Alterations in Gastric Intestinal Metaplasia Shed Light on Alteration of Methionine Metabolism: Insight into New Diagnostic and Treatment Approaches

Knowledge, attitude and antibiotic prescribing patterns of medical doctors providing free healthcare in the outpatient departments of public hospitals in Sierra Leone: A national cross-sectional study

Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity

First total synthesis of a novel amide alkaloid derived from Aconitum taipeicum and its anticancer activity

Methods to treat the industrial wastewater in diosgenin enterprises produced from Diosorea zingiberensis C. H. Wright

Safety investigation on total steroid saponins extracts from Dioscorea zingiberensis C.H. Wright: Sub-acute and chronic toxicity studies on dogs

Hui Huang | Precision Medicine | Best Researcher Award

Published on 05/04/202505/04/2025 by Top Pharmaceutical

Hui Huang | Precision Medicine | Best Researcher Award

Prof. Dr. Hui Huang, The Eighth Affiliated Hospital of Sun Yat-Sen University, China

Prof. Hui Huang is Vice President of The Eighth Affiliated Hospital of Sun Yat-sen University and a renowned expert in vascular calcification and chronic disease prevention. 📚 He has authored 100+ high-impact papers in journals like Circulation and J Clin Invest, earning honors like ESI Highly Cited and Top 100 High-Value Papers. 🏆 A recipient of China’s Excellent Young Scientists Fund, he directs multiple prestigious laboratories and holds several international patents. 🔬 His research explores metabolic and immune mechanisms in chronic kidney disease and vascular aging.

Publication Profile

Scopus

Education

Prof. Dr. Hui Huang has authored over 100 peer-reviewed papers in prestigious journals such as Circulation (2022, 2023), J Clin Invest. (2021, 2022, 2025), Hypertension (2018, 2021, 2022), STTT (2022–2024), Kidney Int. (2024), and Cardiovasc Res. (2023) 📚. His impactful work has earned distinctions like ESI Highly Cited Papers, Top 100 High-Value Papers, and journal Cover Stories 🏅. A recipient of China’s National Science Fund for Excellent Young Scholars 🎓, he also led the development of the Expert Consensus on Vascular Calcification, offering vital clinical guidance for practitioners in the field of cardiovascular and renal medicine ❤️🩺.

Experience

Prof. Dr. Hui Huang has led more than 13 major research projects, predominantly funded by the National Natural Science Foundation of China (NSFC) 🔬🇨🇳. His groundbreaking work focuses on unraveling the innovative mechanisms behind arterial calcification, chronic kidney disease, and inflammation 🧠🫀. These projects are long-term, high-budget, and scientifically robust, highlighting their critical importance on both national and global stages 🌍💰. Through his pioneering research, Prof. Huang is driving transformative advancements in cardiovascular and renal health, contributing significantly to medical science and improving patient outcomes 🚀🩺.

Research Focus

Prof. Dr. Hui Huang is a leading researcher in biomedical sciences, with a strong focus on cardiovascular disease, immunology, toxicology, and metabolic disorders. Her work spans areas such as inflammation in the central nervous system, myocardial infarction, diabetes-related metabolomics, and environmental health risks like metal toxicity. 🌡️🧠🫀 She also explores digital therapeutics and sex-based differences in disease outcomes, making her contributions highly interdisciplinary. 📊💻 Her research integrates clinical, molecular, and environmental insights to develop novel strategies for disease prevention and treatment. A strong advocate for translational medicine, Prof. Huang bridges lab science with real-world health challenges.

Publication Top Notes

The Innate Immune Sensor Zbp1 Mediates Central Nervous System Inflammation Induced by Angiostrongylus Cantonensis by Promoting Macrophage Inflammatory Phenotypes

Targeted LC-MS/MS method of oxylipin profiling reveals differentially expressed serum metabolites in type 2 diabetes mice with panaxynol

Ellagic acid-enhanced biocompatibility and bioactivity in multilayer core-shell gold nanoparticles for ameliorating myocardial infarction injury

Sex difference in human diseases: mechanistic insights and clinical implications

Effect of plateletcrit and methylenetetrahydrofolate reductase (MTHFR) C677T genotypes on folic acid efficacy in stroke prevention

Digital therapeutics in hypertension: How to make sustainable lifestyle changes

Associations of essential metals with the risk of aortic arch calcification: a cross-sectional study in a mid-aged and older population of Shenzhen, China

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Published on 03/04/202503/04/2025 by Top Pharmaceutical

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Dr. Alessandra Tucci, ASST Spedali Civili di Brescia, Italy

Dr. Alessandra Tucci is an esteemed Italian hematologist and Director of the Hematology Unit at ASST Spedali Civili di Brescia. With over three decades of expertise, she specializes in lymphomas, particularly in elderly patients. She holds dual specializations in Allergology & Immunology (University of Florence) and Hematology (University of Milan). A key figure in national and international research, she has led multiple clinical trials and serves on prestigious scientific boards, including the Italian Lymphoma Foundation (FIL) and European Hematology Association (EHA). An accomplished author and peer reviewer, Dr. Tucci continues to advance hematological research.

Publication Profile

Scopus

Education

Dr. Alessandra Tucci 🎓 earned her Doctor of Medicine degree from the University of Brescia in 1987, specializing in Allergology, Immunology, and Hematology. 🩸 Her dual specialization underscores her deep expertise in blood disorders and immune-related conditions. 🏥 Passionate about advancing medical science, she further pursued a Master’s in Management applied to hematology, showcasing her leadership in clinical and research settings. 📚 With a strong foundation in both patient care and scientific innovation, Dr. Tucci continues to make significant contributions to the field, bridging the gap between medical research and practical healthcare solutions. 🔬✨

Experience

Dr. Alessandra Tucci 🔬 is a Principal Investigator in numerous national and international studies, focusing on hematology, particularly lymphomas and hematologic malignancies in elderly patients. 🩸 Her research impact is evident through an impressive H-index of 44 (Scopus) and 48 (Google Scholar), with over 9,792 citations. 📊 She has contributed as a Guest Editor for Special Issues in high-impact journals like Cancers and serves as a reviewer for prestigious publications such as Lancet Haematology and Blood Advances. 📖 Her dedication to advancing hematologic research continues to shape the field and improve patient outcomes worldwide.

Awards

Dr. Alessandra Tucci 🏆 has played a pivotal role in clinical trials (phases I-III), driving innovative treatments in hematology and significantly improving patient care. 🩸 Her contributions extend beyond research, as she actively shapes the scientific community through editorial work, peer reviews, and participation in prestigious scientific boards. 📖🔬 Recognized for her expertise and leadership, she is a respected thought leader whose work influences both clinical practice and future therapeutic advancements. 🌍✨ Through her dedication, Dr. Tucci continues to leave a lasting impact on the field of hematology, inspiring researchers and improving patient outcomes worldwide. 💡👩‍⚕️

Research Focus

Dr. Alessandra Tucci is a distinguished researcher specializing in hematology 🩸, with a focus on lymphomas 🦠, leukemias 🧬, and stem cell transplantation 🏥. Her work extensively explores invasive pulmonary aspergillosis in leukemia, mantle cell lymphoma prognosis, and the impact of radiotherapy on hematologic malignancies. She contributes to clinical trials, geriatric oncology assessments, and advanced imaging techniques like FDG PET/CT 📡 to improve diagnostic precision and treatment outcomes. Dr. Tucci’s research plays a critical role in optimizing chemoimmunotherapy 💉 and personalized medicine for hematologic disorders.

Publication Top Notes

Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda

Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma

A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2-[¹⁸F]FDG PET/CT in Advanced Mantle Cell Lymphoma

Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome Medicine, (2023), 15, 1, (22), 10.1186/s13073-023-01173-8)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial

2-[¹⁸]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome

Michael Harrison | Precision Medicine | Best Researcher Award

Published on 28/03/202528/03/2025 by Top Pharmaceutical

Michael Harrison | Precision Medicine | Best Researcher Award

Dr. Michael Harrison, UCSF, United States

Dr. Michael Harrison is a pioneering pediatric surgeon and fetal therapy expert. 🎓 He earned his B.A. from Yale (1965) and M.D. from Harvard Medical School (1969), followed by extensive surgical training at Massachusetts General Hospital and fellowships in pediatric surgery. 🏥 He joined UCSF in 1978, where he became a Full Professor and founded the Fetal Treatment Center. 👶 His groundbreaking work in fetal surgery has earned him numerous accolades, including the Golden Plate Award and presidency of the International Fetal Medicine and Surgery Society. 🌍 Now Professor Emeritus at UCSF, he continues to shape the field of pediatric surgery. ✨

Publication Profile

Scopus

Education

Dr. Michael Harrison 🎓 began his academic journey at Yale University (1961-1965), earning a B.A. before pursuing his M.D. in Medicine at Harvard Medical School (1965-1969) 🏥. He completed his surgical residency at Massachusetts General Hospital (1969-1971) and advanced his expertise as a Postdoctoral Fellow in Allergy & Immunology at the National Institute of Allergy and Infectious Disease (1971-1973) 🧬. Returning to Massachusetts General, he served as a Senior Resident (1973-1974) and Chief Resident (1974-1975) 🔬. Further specializing, he completed fellowships in Pediatric Surgery at Rikshospitalet (1975-1976) 🇳🇴 and Children’s Hospital of Los Angeles (1976-1978) 👶🩺.

Experience

Dr. Michael Harrison 🏥 has been a Founding Member of the International Fetal Medicine and Surgery Society (1981-present) 👶 and has served as its President at the Annual Meeting (1989, 2006) 🎤. He has contributed as a Committee Member for the Medical Advisory Committee of the American Association of Tissue Banks (1993-present) 🧬 and chaired the Committee on Fetal Therapy at APSA (1994-1996) 🏥. A Board Member of the International Society of the Fetus as Patient (1997-present) 🌍, he also consults for the MOMS study (2003-present) 🤰. Since 2010, he has been Vice President of the California Academy of Medicine 📚.

Awards

Dr. Michael Harrison 🏅 has received numerous prestigious honors, including the Golden Plate Award (1982, 1988) 🏆, the William E. Ladd Medal (2010) 🏅, and the Lifetime Achievement Award (2011) 🌟 from the International Fetal Medicine and Surgery Society. He was elected to the Institute of Medicine (2009) 📜 and honored with the Denis Browne Gold Medal (2013) 🏵️. As a celebrated lecturer, he has delivered keynote addresses worldwide 🌍, including at the Nobel Minisymposium on Fetal Medicine (1998) 🎤. His groundbreaking contributions in pediatric surgery have earned him global recognition and lasting influence in the field.

Research Focus

Dr. Michael R. Harrison is a pioneering surgeon and researcher in pediatric surgery and fetal therapy 🏥👶. His work focuses on maternal-fetal surgery, particularly for conditions like esophageal atresia and diaphragmatic hernia. He has contributed to the development of magnetic compression anastomosis 🧲 and other innovative minimally invasive surgical devices 🔬. His research advances the treatment of complex congenital disorders and improves outcomes for newborns. With numerous publications, he has significantly impacted pediatric device clinical trials 📊. Dr. Harrison’s groundbreaking contributions continue to shape the future of pediatric and fetal surgical care 🚼✨.

Publication Top Notes

Pediatric Device Clinical Trials Activity: 1999–2022

Lessons Learned From the First-In-Human Compassionate Use of Connect-EA™ in Ten Patients With Esophageal Atresia

Evaluation of a Magnetic Compression Anastomosis for Jejunoileal Partial Diversion in Rhesus Macaques

Sonographic Predictors of Survival in Fetal Diaphragmatic Hernia

Beyond the gut: spectrum of magnetic surgery devices

The Rearing of Maternal–Fetal Surgery: The Maturation of a Field from Conception to Adulthood

The novel application of an emerging device for salvage of primary repair in high-risk complex esophageal atresia

Esophageal Magnetic Compression Anastomosis in Esophageal Atresia Repair: A PRISMA-Compliant Systematic Review and Comparison with a Novel Approach

An experimental study on long term outcomes after magnetic esophageal compression anastomosis in piglets

Novel device for endoluminal esophageal atresia repair: First-in-human experience